Category - Developments

Developments

Fractyl increases focus on key gene therapy programs

Fractyl Health (NASDAQ:GUTS) has announced plans to prioritize its REMAIN-1 pivotal study, advance its novel Rejuva gene therapy platform into first-in-human studies, and pause investment in its Revita programs for Type...

January 31, 2025

Developments

INBS upgrades portable drug screening reader with multilingual capabilities

Intelligent Bio Solutions (INBS) (NASDAQ:INBS) has announced plans to upgrade its drug screening reader, the Intelligent Fingerprinting Drug Screening System, to support multiple languages across North and South...

January 31, 2025

Developments

HeartBeam files 510(k) application with FDA for ECG software

HeartBeam (NASDAQ:BEAT) has announced the submission of a 510(K) application to the FDA for its 12-lead electrocardiogram (ECG) synthesis software, designed to analyze diverse cardiac rhythms and arrhythmias, leveraging...

January 30, 2025

Developments

HOOKIPA completes enrollment in Phase 1b study of HB-500 in HIV

HOOKIPA Pharma (NASDAQ:HOOK) has announced the completion of enrollment for its Phase 1b trial evaluating HB-500 in patients with HIV. The company stated that the study is comprised of two dose-escalation cohorts, with...

January 30, 2025

Developments

Tectonic announces positive Phase 1b results for TX45 in HFpEF

Tectonic Therapeutic (NASDAQ:TECX) has announced positive interim data from its Phase 1b acute hemodynamic clinical trial of TX45 in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH...

January 30, 2025

Developments

Polyrizon files patent application with ILPO for T&T technology

Polyrizon (NASDAQ:PLRZ) has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO). The company stated...

January 30, 2025

Developments

Model Medicines unveils AI-driven pipeline breakthrough; demonstrates end-to-end drug discovery capabilities

Closely held Model Medicines has announced the unveiling of a generative AI-driven, multi-modal therapeutic pipeline breakthrough, showcasing its end-to-end drug discovery capabilities for novel target discovery...

January 28, 2025

Developments

NLS launches preclinical program for Mazindol ER in fentanyl addiction

NLS Pharmaceutics (NASDAQ:NLSP; NASDAQ:NLSPW) has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence. According to the Centers for Disease Control and...

January 28, 2025

Developments

Conduit partners with Sarborg to advance drug development with AI

Conduit Pharmaceuticals (NASDAQ:CDT) has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed. The company...

January 28, 2025

Developments

Stereotaxis receives CE Mark for cardiac ablation catheter

Stereotaxis (NYSE:STXS) has announced that it has received European CE Mark approval for its MAGIC ablation catheter, designed to perform cardiac ablation procedures aimed at treating heart arrhythmia. According to...

January 27, 2025

Category - Developments

Fractyl increases focus on key gene therapy programs

INBS upgrades portable drug screening reader with multilingual capabilities

HeartBeam files 510(k) application with FDA for ECG software

HOOKIPA completes enrollment in Phase 1b study of HB-500 in HIV

Tectonic announces positive Phase 1b results for TX45 in HFpEF

Polyrizon files patent application with ILPO for T&T technology

Model Medicines unveils AI-driven pipeline breakthrough; demonstrates end-to-end drug discovery capabilities

NLS launches preclinical program for Mazindol ER in fentanyl addiction

Conduit partners with Sarborg to advance drug development with AI

Stereotaxis receives CE Mark for cardiac ablation catheter

General

More